MedTrace Logo

A Study of the Effect of Daridorexant on Nighttime Body Posture, the Noise Level Required to Wake up, and the Ability to Remember Words Previously Presented

NCT05702177 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2023-05-12

No results posted yet for this study

Summary

A Study of the Effect of Daridorexant on Nighttime Body Posture, the Noise Level Required to Wake up, and the Ability to Remember Words Previously Presented

Conditions

  • Healthy

Interventions

DRUG

Daridorexant 25 mg

A single-dose of daridorexant 25 mg will be administered in the evening 30 minutes prior to bedtime.

DRUG

Daridorexant 50 mg

A single-dose of daridorexant 50 mg will be administered in the evening 30 minutes prior to bedtime.

DRUG

Placebo

A single-dose of placebo matching daridorexant will be administered in the evening 30 minutes prior to bedtime.

Sponsors & Collaborators

  • Idorsia Pharmaceuticals Ltd.

    lead INDUSTRY

Principal Investigators

  • Clinical Trials · Idorsia Pharmaceuticals Ltd.

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-01-05
Primary Completion
2023-04-25
Completion
2023-04-25
FDA Drug
Yes

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05702177 on ClinicalTrials.gov